NeoDynamics, Inc., a MedTech company, announced the US availability of NeoNavia, the first and only biopsy system built on a patented pulse technology for controlled and precise needle insertion.
NeoNavia will be commercially introduced at The American Society of Breast Surgeons (ASBrS) 24th Annual Meeting at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts through Sunday and the following week, at the SBI Breast Imaging Symposium, May 4-7, 2023, at the Gaylord National Resort & Convention Center in National Harbor, Maryland. ASBrS serves as the primary leadership organization for general surgeons who treat patients with breast disease and has grown to more than 3,000 members in the United States and 35 countries throughout the world. SBI is the leading network of breast radiologists and medical physicists in the US.
The NeoDynamics commercial team will be providing hands-on workshops and demonstrations of the NeoNavia system to demonstrate the precision and control with pulse technology as well as the FlexiPulse retractable, open-tip needle which produces up to a 299% larger sample than side-notch core needle systems.
